Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone Safety Extension Study in Children With Chronic Kidney Disease and Proteinuria
NCT05457283Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Nov 2022
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of finerenone in chronic kidney disease (CKD), proteinuria, sponsored by Bayer. Started Nov 2022; status: recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)proteinuria
Beyond the preview
Go deeper on NCT05457283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457283.